The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The umbilical is the standard option for delivery for commercial diving operations. It contains a hose to supply the breathing gas and usually several other components, which may be stipulated by legislation or code of practice. These usually include a communications cable (comms wire), a pneumofathometer, and a strength member, which may be the airline hose, the communications cable, or a rope. When needed, a hot water supply line, helium reclaim line, video camera and lighting cables may be included. These components are bundled and taped, or neatly twisted into a multistrand cable, and are deployed as a single unit. The diver's end has underwater connectors for the electrical cables, and the air hoses are usually connected to the helmet, band mask, or bailout block by JIC fittings. A screw-gate carabiner or similar connector is provided on the strength member for attachment to the diver's harness, and may be used to lift the diver in an emergency. Similar connections are provided for attachment to the diving bell, if used, or to the surface gas panel and communications equipment. A diver's umbilical supplied from a bell gas panel is called an excursion umbilical, and the supply from the surface to the bell panel is the bell umbilical.
He received a B.S. in physics in 1943. He did not attend graduate school, instead deciding to join the Fighting Vehicles Research Establishment where he served between 1943 and 1947 developing tank fire-control systems.
The taxonomic workforce remains insufficient for documenting lichen diversity. Lendemer (2021) found that only 14% of lichen-related research papers published in 2018–2020 included taxonomic work, while Lücking (2020) estimated that the current community of lichen taxonomists is only a fraction of what would be needed for a complete inventory. Expertise is particularly lacking in biodiversity-rich tropical regions where most undescribed species likely occur. However, infrastructure improvements are helping address these gaps. Since 2012–2013, mandatory registration of new fungal names in repositories like MycoBank has been widely adopted, with over 97% of new lichen species from 2018 to 2020 properly registered. Additionally, citizen scientists using platforms such as iNaturalist increasingly contribute to species discovery when collaborating with professional taxonomists. Nomenclatural challenges arise as lichen systematics increasingly encounters cryptic species. Environmental DNA studies reveal numerous uncharacterized fungal lineages, including potential lichenicolous fungi, but ICN rules require physical type specimens for species description. This creates difficulties for documenting diversity found only in environmental samples. The community generally discourages naming taxa known only from sequences to avoid proliferating dubious names. A related concern is taxonomic inflation—the risk that genomic data could lead to naming every population variant.
Before isolating the gas, they had determined that nitrogen produced from chemical compounds was 0.5% lighter than nitrogen from the atmosphere. The difference was slight, but it was important enough to attract their attention for many months. They concluded that there was another gas in the air mixed in with the nitrogen. Argon was also encountered in 1882 through independent research of H. F. Newall and W. N. Hartley. Each observed new lines in the emission spectrum of air that did not match known elements. Prior to 1957, the symbol for argon was "A". This was changed to Ar after the International Union of Pure and Applied Chemistry published the work Nomenclature of Inorganic Chemistry in 1957.
Sources: en.wikipedia.org
11 January 1919: The Germans recapture Sarnowa and win in Battle of Zbąszyń; Polish victory in Battle of Szubin and capture Łabiszyn, Złotniki and Żnin. 12 January 1919: fighting near Leszno and Lipno. 13 January 1919: The Germans recapture Szamocin. 14 January 1919: The Commission of the NRL appeals to Roman Dmowski for help negotiate a ceasefire. 15 January 1919: failed attempt to recapture Szamocin by Poles. 16 January 1919 The first number of Tygodnik Urzędowy Naczelnej Rady Ludowej, with the laws of the NRL, is published. The Polish government of Ignacy Paderewski has two politicians of Greater Poland: Józef Englich, the minister of treasury, and Kazimierz Hącia, the minister of industry and trade. 17 January 1919: Men born in 1897, 1898, and 1899 are called up and drafted into Great Polish Army. 20 January 1919: the transfer of money to banks of Germany on the other side of the front line is forbidden. 21 January 1919 NRL creates oath of soldiers of Great Polish Army. 22 January 1919 Northern front: Poles are forced to leave Potulice. Southern front: Poles win the Battle of Robaczysko. Joseph Noulens is nominated by Supreme Council of Allied Countries as chief of Allied mission in Poland. 23 January 1919: Poles defend Miejska Górka after heavy fighting. 25 January 1919 Poles capture Babimost and Kargowa. All communication between Greater Poland and Germany is broken. Decree cancels Prussian prohibition of Polish language in schools.
=== Optical modulator === When the Fermi level of graphene is tuned, its optical absorption can be changed. In 2011, researchers reported the first graphene-based optical modulator. Operating at 1.2 GHz without a temperature controller, this modulator has a broad bandwidth (from 1.3 to 1.6 μm) and small footprint (~25 μm2). A Mach-Zehnder modulator based on a hybrid graphene-silicon waveguide has been demonstrated recently, which can process signals nearly chirp-free. An extinction up to 34.7 dB and a minimum chirp parameter of -0.006 are obtained. Its insertion loss is roughly -1.37 dB.
fMLF and a sampling of other, less potent, N-formyl oligopeptides were then found to stimulate a wide array of rabbit neutrophil functions such as: the transient auto-aggregation of these cells in suspension and equally transient fall in circulating neutrophils when injected into rabbit veins (these responses result from an increase in neutrophil adhesiveness to each other and/or vascular endothelium); the release (see degranulation) of intracellular granule-bound enzymes and other antimicrobial cytotoxic molecules; and the production and release of cytotoxic reactive oxygen species such as superoxide and hydrogen peroxide. All of these responses are part of the innate immune systems initial line of defense against bacterial invasions. Follow-up studies found that the genes of mitochondria and chloroplasts of eukaryotic cells, including the mitochondria of humans, release N-formyl-methionyl containing peptides with chemotactic activities that exactly mimic those of fMLF. These organelle-derived formylated peptides are true analogs of fMLF that operate through fMLF receptors to recruit circulating blood leukocytes to and thereby initiate inflammation responses at sites of cell damage and tissue destruction not caused by bacteria. Thus, fMLF can act as a find-me signal, released by dead or dying cells to attract phagocytes to those cells, so that the phagocytes phagocytose the dead or dying cells, thereby clearing up the damage. fMLF and other N-formylated oligopeptides were found to be similarly active in human neutrophils.
Sources: en.wikipedia.org
==== Current usage in medicine ==== Desmosine is currently used as a biomarker in the medical field. It is measured in order to monitor elastin breakdown. Since it is connected to the degradation of elastin, it can be used to identify COPD. Desmosine is one of the oldest biomarkers and was developed in the 1960s, but the first time it was correlated to lung elastin content was in the 80s through urinary excretion. Biomarkers are judged in 6 ways:
=== UFC merged with WWE to form TKO Group === In April 2023, Endeavor Group Holdings announced that UFC would merge with the wrestling promotion WWE to form TKO Group Holdings, a new Public company majority-owned by Endeavor, with Vince McMahon serving as an executive chairman of the new entity and White remaining as UFC president. The merger was completed on September 12, 2023.
== Research == Methenamine might be useful in the treatment of Helicobacter pylori infections as it is activated in the acidic environment of the stomach. The drug can safely be used intravenously and might be useful in the treatment of central nervous system infections as well as certain cancers.
For example, many mutations lower the stability of proteins, while ligand binding usually increases protein stability. Using DSC, this stability can be measured by obtaining Gibbs Free Energy values at any given temperature. This allows researchers to compare the free energy of unfolding between ligand-free protein and protein-ligand complex, or wild type and mutant proteins. DSC can also be used in studying protein/lipid interactions, nucleotides, drug-lipid interactions. In studying protein denaturation using DSC, the thermal melt should be at least to some degree reversible, as the thermodynamics calculations rely on chemical equilibrium.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.